Heparin-induced thrombocytopenia (HIT) stands as a critical complication arising from exposure to heparin products, irrespective of the form or quantity. Characterized by a decline in platelet counts and a prothrombotic state, HIT can precipitate severe thromboembolic events, leading to significant morbidity and mortality. Given the widespread use of heparin in thromboembolism treatment and prophylaxis, catheter flushes, and heparin-coated devices, HIT poses a substantial clinical challenge. This article delves into the pathophysiology, Hit Medical Diagnosis, and therapeutic strategies for heparin-induced thrombocytopenia, emphasizing the crucial role of an interprofessional healthcare team in patient care.
Objectives:
- To delineate the clinical presentation of heparin-induced thrombocytopenia.
- To elucidate the potential complications associated with heparin-induced thrombocytopenia.
- To review the current treatment guidelines for heparin-induced thrombocytopenia.
- To emphasize the importance of a collaborative, interprofessional approach in identifying and managing patients at risk for heparin-induced thrombocytopenia.
Access free multiple choice questions on this topic.
Introduction
Heparin-induced thrombocytopenia (HIT) is a serious complication that can occur in patients exposed to heparin. It is defined by a decrease in platelet count and an increased risk of blood clots. The risk is significant because heparin is frequently used in medicine to prevent and treat blood clots, maintain intravenous lines, and coat medical devices. This article will explore the underlying mechanisms, HIT medical diagnosis, and effective treatments for patients affected by HIT.
Etiology of HIT
Two primary types of thrombocytopenia are linked to heparin administration:
Type I HIT, also known as heparin-associated thrombocytopenia (HAT), is a common, non-immune reaction. It can manifest as early as the first day of heparin therapy. Type I HIT is typically mild, not associated with thrombotic complications, and platelet counts often return to normal even with continued heparin use.
Type II HIT is an immune-mediated condition, triggered by antibodies. Antibody formation takes time; therefore, type II HIT usually develops 5 to 14 days after starting heparin. However, in patients with prior heparin exposure within the preceding 100 days, pre-existing antibodies can lead to rapid onset, sometimes within 24 hours of re-exposure. Type II HIT is a severe condition characterized by a hypercoagulable state and a high risk of life-threatening thromboembolic complications. The subsequent discussion will primarily focus on type II HIT, its medical diagnosis, and management.
Epidemiology of HIT
HIT can affect up to 5% of patients treated with heparin products. It induces a significant hypercoagulable state, with thromboembolic complications occurring in as many as 50% of patients, and mortality rates reaching up to 30%.
Several factors, both medication-related and patient-specific, influence HIT risk. Unfractionated heparin (UFH) is more strongly associated with HIT compared to low molecular weight heparin (LMWH) due to structural and functional differences. Fondaparinux, a synthetic heparin analog, does not typically cause HIT and exhibits minimal cross-reactivity with heparin-induced antibodies. UFH is composed of long, varied saccharide chains, averaging 45 units in length. LMWH consists of shorter chains, averaging around 15 saccharide units. Fondaparinux, being a pentasaccharide, has only 5 sugar units. Drugs with shorter saccharide chains and lower molecular weights exhibit reduced binding to plasma proteins and cells, thus lowering the risk of HIT. Consequently, LMWH carries a lower HIT risk than UFH, while fondaparinux is considered safe in patients with a history of HIT and is a viable option for acute HIT treatment.
While HIT can occur with any heparin dose, higher doses and prolonged therapy duration increase the risk. Additionally, females and elderly individuals appear to be at higher risk. Surgical patients also have an elevated HIT incidence, potentially due to increased platelet activation and PF4 release from surgical trauma and intervention.
Pathophysiology of HIT
Platelet factor 4 (PF4), a positively charged protein, is normally stored in platelet alpha-granules and released upon platelet activation. PF4 can bind to heparan, a negatively charged substance on endothelial cells, and exhibits a stronger affinity for exogenous heparin.
The binding of PF4 to heparin can initiate the formation of IgG, IgA, or IgM antibodies specific to the heparin-PF4 complex. HIT pathogenesis primarily involves IgG antibodies. When IgG antibodies bind to the heparin-PF4 complex and then to platelet Fc receptors, platelet activation occurs. Activated platelets release prothrombotic substances like thrombin and further PF4. This cascade amplifies as more platelets are activated by IgG, leading to a hypercoagulable state and a self-perpetuating cycle that is only interrupted by heparin cessation and appropriate treatment.
Thrombocytopenia, a hallmark of HIT, arises from two mechanisms. First, macrophages in the reticuloendothelial system consume IgG-coated platelets, reducing platelet counts. Second, platelet activation and aggregation contribute to thrombus formation, further decreasing circulating platelets.
The hypercoagulable state in HIT predisposes patients to venous and arterial thrombosis. Common complications include deep vein thrombosis (DVT), pulmonary embolism (PE), and skin necrosis, particularly with warfarin initiation in the acute phase. The highest risk period for these complications is within the first 10 days, but the prothrombotic state can persist for up to 30 days post-heparin discontinuation.
History and Physical Examination in HIT
Clinical presentation of HIT can include sudden pain, redness, and swelling in an arm or leg, indicative of thrombosis. Ecchymotic lesions may also appear. Localized reactions, such as rash or soreness, can develop at heparin injection sites. Patients may report weakness, numbness, or impaired limb movement.
The most frequent symptom of HIT is the worsening of an existing blood clot or the development of a new thrombus, affecting both arteries and veins. Venous thromboses can manifest as deep vein thrombosis (DVT) in the extremities and pulmonary embolism (PE) when clots migrate to the lungs.
In patients receiving intravenous heparin, systemic symptoms may emerge, including chills, fever, hypertension, tachycardia, shortness of breath, and chest pain. Some patients may develop a petechial rash, characterized by small red spots on the skin.
Evaluation and Medical Diagnosis of HIT
HIT medical diagnosis should be considered in any patient on heparin or recently exposed to heparin who develops an unexplained drop in platelet count. HIT typically presents with a consistent decrease in platelet counts without significant fluctuations, while hemoglobin and hematocrit levels remain relatively stable.
The initial step in HIT medical diagnosis is often the 4Ts scoring system. This clinical assessment tool estimates the probability of HIT based on four parameters:
| 4T Score Component | 2 Points (High) | 1 Point (Intermediate) | 0 Points (Low) |
|---|---|---|---|
| Thrombocytopenia | Platelet count fall ≥50% AND nadir ≥20 x 10^9/L | Platelet count fall 30-50% OR nadir 10-19 x 10^9/L | Platelet count fall <30% OR nadir ≥20 x 10^9/L |
| Timing of Platelet Fall | 5-10 days OR ≤1 day if prior heparin exposure in 30-100 days | 5-10 days BUT onset unclear OR ≤1 day if prior heparin exposure >100 days OR onset after day 10 | <4 days without prior heparin exposure |
| Thrombosis or Sequelae | New thrombosis (confirmed) OR skin necrosis OR anaphylactoid reaction | Progressive or recurrent thrombosis OR suspected thrombosis (not proven) OR erythematous rash | None |
| Other Causes for Thrombocytopenia | None apparent | Possible | Definite |
A 4Ts score of 0 to 3 indicates a low probability of HIT, allowing for continued heparin therapy while investigating other causes of thrombocytopenia. A score of 4 to 5 suggests intermediate probability, and 6 to 8 indicates high probability. In patients scoring 4 or higher, all heparin products, including flushes, heparin-coated catheters, and heparin in dialysate, should be immediately discontinued, and alternative anticoagulation initiated. HIT medical diagnosis based on the 4Ts score must be confirmed with laboratory testing, primarily the PF4 ELISA and Serotonin Release Assay (SRA).
The PF4 ELISA is a highly sensitive immunoassay used in HIT medical diagnosis to detect heparin-PF4 antibodies. Its high sensitivity and negative predictive value are useful for ruling out HIT if negative. However, the PF4 ELISA has lower specificity, leading to false positives. This is because it detects IgG, IgA, and IgM antibodies, while only IgG is directly pathogenic in HIT. A positive ELISA is typically defined as an optical density (OD) greater than 0.4. Higher OD values correlate with a greater likelihood of true HIT and thrombosis risk. Retrospective data indicates that less than 3% of patients with an OD between 0.4 and 1 will have confirmed HIT. The American Society of Hematology (ASH) guidelines recommend confirmatory SRA testing for all positive ELISA results. However, if SRA is unavailable, a strongly positive ELISA with an OD greater than 2 (associated with approximately 90% probability of HIT) can support HIT medical diagnosis.
If the PF4 ELISA is positive, confirmation with SRA is recommended. SRA is considered the gold standard functional assay for HIT medical diagnosis due to its high sensitivity and specificity. Unlike ELISA, which detects antibodies, SRA assesses platelet activation in the presence of antibodies. The assay measures serotonin release from donor platelets when exposed to heparin and patient serum (containing IgG antibodies). A positive SRA confirms HIT medical diagnosis, while a negative SRA generally rules out HIT, even with a positive ELISA.
Treatment and Management of HIT
Treatment for HIT should commence immediately upon calculating a 4Ts score of 4 or higher, even before definitive HIT medical diagnosis confirmation. The first critical step is to discontinue all forms of heparin exposure. For patients recently started on warfarin, it should be withheld, and vitamin K administered to replenish protein C and S levels. Simultaneously, blood samples should be sent for PF4 ELISA and SRA to confirm the HIT medical diagnosis.
According to the 2018 ASH guidelines, therapeutic-dose alternative anticoagulation is recommended for most patients with suspected or confirmed HIT, including:
- Patients with a high-probability 4Ts score (6-8).
- Patients with an intermediate-probability 4Ts score (4-5) and another indication for therapeutic anticoagulation.
- Patients with an intermediate-probability 4Ts score (4-5) without another indication for therapeutic anticoagulation, unless at high bleeding risk.
Prophylactic-dose alternative anticoagulation may be considered in a small subset of patients at high bleeding risk who do not require therapeutic anticoagulation for other reasons and have an intermediate probability 4Ts score. If prophylactic anticoagulation is initiated and the immunoassay returns positive, transition to therapeutic anticoagulation is necessary pending SRA results.
Current guidelines recommend several alternative anticoagulants, including argatroban, bivalirudin, danaparoid, fondaparinux, and direct oral anticoagulants (DOACs).
Argatroban and bivalirudin, direct thrombin inhibitors with short half-lives, are suitable for critically ill patients, those at high bleeding risk, or those needing urgent procedures. Argatroban does not interact with PF4 or heparin-induced antibodies and has a half-life of 39-51 minutes. It is administered as a continuous infusion, titrated to maintain an aPTT 1.5–3 times baseline. Hepatic metabolism necessitates dose adjustments and frequent aPTT monitoring in patients with hepatic dysfunction, heart failure, or multi-organ failure. Argatroban falsely elevates INR, which does not reflect bleeding risk but complicates warfarin bridging.
Bivalirudin, another direct thrombin inhibitor, is also safe in HIT but is often reserved for cardiac catheterization or surgery as a heparin alternative. It is FDA-approved for percutaneous coronary intervention with or without HIT and is more costly than argatroban.
Fondaparinux, while not FDA-approved for HIT, is considered safe and effective and is ASH guideline-recommended. It is administered as a once-daily subcutaneous injection. Renal clearance is a key consideration, and it is contraindicated in patients with severe renal impairment (CrCl <30 mL/min).
Prior to the 2018 ASH guidelines, acute HIT treatment primarily involved parenteral anticoagulants like argatroban and fondaparinux. However, increasing evidence supports the efficacy and safety of DOACs, particularly rivaroxaban. Current guidelines now list DOACs as acceptable treatment options. Dosing recommendations are extrapolated from VTE treatment guidelines, and VTE contraindications also apply to DOAC use in HIT.
Differential Diagnosis
The differential diagnosis for HIT includes other conditions causing thrombocytopenia, such as type I HIT (HAT), disseminated intravascular coagulation (DIC), liver disease, bleeding, hemodilution, immune thrombocytopenia (ITP), myelosuppression, and other drug-induced thrombocytopenias.
- Bacterial sepsis
- Disseminated intravascular coagulation
- Drug-induced thrombocytopenia (other than heparin)
- Hemolytic-uremic syndrome
- Immune thrombocytopenia
- Splenomegaly
- Thrombotic thrombocytopenic purpura
- Transfusion reactions
Pearls and Other Key Considerations
The American Society of Hematology defines five phases of HIT:
- Suspected HIT: Clinical suspicion based on clinical findings.
- Acute HIT: HIT medical diagnosis confirmed by a positive SRA.
- Subacute HIT A: Occurs around day 7 post-heparin cessation; platelet counts recovered, but SRA remains positive, indicating persistent pathogenic antibodies.
- Subacute HIT B: Period after SRA becomes negative but before immunoassay (ELISA) becomes negative. Antibodies are present but no longer pathogenic. SRA typically becomes negative around 50 days post-heparin.
- Remote HIT: Antibodies are no longer detectable by immunoassay, typically around 85 days post-heparin.
Management of suspected and acute HIT has been detailed earlier. Absolute contraindications in the acute phase include UFH, LMWH, warfarin, and platelet transfusions. Warfarin initiation in acute HIT can worsen hypercoagulability due to initial depletion of vitamin K-dependent protein C and S, increasing thromboembolic risks, especially skin necrosis. If warfarin was recently started, it should be stopped and reversed with phytonadione.
Warfarin can be restarted when platelet counts have substantially recovered and stabilized, ideally reaching at least 150,000/µL or the patient’s baseline if lower. Therapeutic anticoagulation with argatroban or fondaparinux must be established before warfarin initiation, with an overlap of at least 5 days before transitioning to warfarin monotherapy.
Platelet transfusions are contraindicated in acute HIT as they can exacerbate the hypercoagulable state by providing more platelets for activation and PF4 release.
Subacute HIT (A and B) is further categorized into isolated HIT and HIT with thrombosis (HITT). For isolated HIT, anticoagulation for 1 month is recommended due to the persistent thromboembolic risk. For HITT, 3 months of anticoagulation is suggested, considering HIT a reversible provoking risk factor for thrombosis. DOACs are now preferred over warfarin in these phases for patients without DOAC contraindications.
Following a HIT episode, IgG antibodies can persist for up to 100 days (median 85 days). Heparin re-exposure during this period can rapidly induce thrombocytopenia, sometimes within 12 hours. After 100 days, heparin can be cautiously reintroduced at the lowest effective dose for the shortest duration if necessary. Ideally, a negative SRA should be confirmed before heparin re-use. If SRA is not feasible, direct thrombin inhibitors or fondaparinux should be considered. Bivalirudin is the preferred agent for patients undergoing PCI or CABG.
Enhancing Healthcare Team Outcomes in HIT Management
Distinguishing clinical features of HIT from other causes of thrombocytopenia include the timing of onset relative to heparin exposure and the presence of thrombosis. Bleeding is not typical in HIT. HIT onset usually occurs 5-14 days after heparin initiation or after heparin cessation. Optimal outcomes in HIT management depend on the vigilance of clinicians, nurses, and pharmacists in recognizing HIT signs and symptoms and prompt communication within the healthcare team. An interprofessional, collaborative approach to HIT medical diagnosis and treatment is essential for achieving the best patient outcomes. [Level 5]
Review Questions
(Note: Review questions are available via the provided StatPearls link at the beginning of this article.)
References
1.Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management. Vasc Med. 2020 Apr;25(2):160-173. [PubMed: 32195628]
2.Nonaka T, Harada M, Sumi M, Ishii W, Ichikawa T, Kobayashi M. A Case of Heparin-Induced Thrombocytopenia That Developed in the Therapeutic Course of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Case Rep Rheumatol. 2019;2019:2724304. [PMC free article: PMC6679837] [PubMed: 31428502]
3.Bloom MB, Johnson J, Volod O, Lee EY, White T, Margulies DR. Improved prediction of HIT in the SICU using an improved model of the Warkentin 4-T system: 3-T. Am J Surg. 2020 Jan;219(1):54-57. [PMC free article: PMC6917902] [PubMed: 31400811]
4.Gallo T, Curry SC, Padilla-Jones A, Heise CW, Ramos KS, Woosley RL, Raschke RA. A computerized scoring system to improve assessment of heparin-induced thrombocytopenia risk. J Thromb Haemost. 2019 Feb;17(2):383-388. [PubMed: 30552743]
5.Solanki J, Shenoy S, Downs E, Palkimas S, Goldman S, Sharma AM. Heparin-Induced Thrombocytopenia and Cardiac Surgery. 2019 AutumnSemin Thorac Cardiovasc Surg. 31(3):335-344. [PubMed: 30448485]
6.Stoll F, Gödde M, Leo A, Katus HA, Müller OJ. Characterization of hospitalized cardiovascular patients with suspected heparin-induced thrombocytopenia. Clin Cardiol. 2018 Dec;41(12):1521-1526. [PMC free article: PMC6490101] [PubMed: 30144122]
7.Fathi M. Heparin-induced thrombocytopenia (HIT): Identification and treatment pathways. Glob Cardiol Sci Pract. 2018 Jun 30;2018(2):15. [PMC free article: PMC6062760] [PubMed: 30083545]
8.Tafesh L, Summerfield G. Thrombocytopenic emergencies. Br J Hosp Med (Lond). 2019 Feb 02;80(2):C18-C21. [PubMed: 30747002]
9.Mazurov AV, Khaspekova SG, Vasiliev SA. Diagnostics of thrombocytopenias. Ter Arkh. 2018 Aug 17;90(7):4-13. [PubMed: 30701917]
10.Marchetti M, Barelli S, Zermatten MG, Monnin-Respen F, Matthey-Guirao E, Nicolas N, Gomez F, Goodyer M, Gerschheimer C, Alberio L. Rapid and accurate Bayesian diagnosis of heparin-induced thrombocytopenia. Blood. 2020 Apr 02;135(14):1171-1184. [PubMed: 31945147]
11.Condon AJ, Hood AJ, Willenborg KL, Kumfer K, Rose AE. Pharmacist involvement in clinical assessment and laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2020 Jul;50(1):195-200. [PubMed: 31802415]
12.Liederman Z, Van Cott EM, Smock K, Meijer P, Selby R. Heparin-induced thrombocytopenia: An international assessment of the quality of laboratory testing. J Thromb Haemost. 2019 Dec;17(12):2123-2130. [PubMed: 31420903]
13.Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007 Sep;83(983):575-82. [PMC free article: PMC2600013] [PubMed: 17823223]
14.Guo Q, Lou Y, Liu L, Luo P. How Can I Manage Thrombocytopenia in Hemodialysis Patient? A Review. Ther Apher Dial. 2020 Aug;24(4):352-360. [PubMed: 31661590]
15.Pollak U. Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support: Review of the literature and alternative anticoagulants. J Thromb Haemost. 2019 Oct;17(10):1608-1622. [PubMed: 31313454]
16.Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018 Nov 27;2(22):3360-3392. [PMC free article: PMC6258919] [PubMed: 30482768]
17.Bambrah RK, Pham DC, Rana F. Argatroban in heparin-induced thrombocytopenia: rationale for use and place in therapy. Ther Adv Chronic Dis. 2013 Nov;4(6):302-4. [PMC free article: PMC3807762] [PubMed: 24179672]
18.Grouzi E. Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II. J Blood Med. 2014;5:131-41. [PMC free article: PMC4140228] [PubMed: 25152637]
Disclosures: Diala Nicolas, Samar Nicolas, Alexander Hodgens, and Mirembe Reed declare no relevant financial relationships with ineligible companies.
